The standard treatment for ER-positive, HER2-negative MBC is a combination of hormone therapy plus a CDK4/6 inhibitor: palbociclib (Ibrance®), ribociclib (Kisqali®), or abemaciclib (Verzenio®). However, over time, people often develop resistance to CDK4/6 inhibitors, which means the drugs stop working. Efforts are underway to predict who is likely to develop resistance before treatment begins and to overcome resistance after treatment has started.
Click the links below to learn about new strategies being studied in clinical trials to overcome resistance to CDK4/6 inhibitors.
CDK4/6 Inhibitor Resistance
- University of Colorado: A CDK2 inhibitor may help overcome resistance to CDK4/6 inhibitors
- American Association for the Advancement of Science: Denosumab (Prolia®) could help overcome resistance to CDK4/6 inhibitors
- Cancer Therapy Advisor: Immunotherapy provides a small improvement in progression-free survival in people who have stopped responding to palbociclib
Clinical Trials That Include CDK Inhibitors
- Metastatic Trial Search: MBC Trials That Include CDK Inhibitors
- Solid Tumor Trials: Use Search Term “CDK” to Find Trials That Include CDK Inhibitors
Last Modified on October 2, 2023